Perreault C, Gyger M, Boileau J, Bonny Y, Cousineau S, Lacombe M, Lavallee R, Tawil E, D'Angelo G
Can Med Assoc J. 1983 Nov 1;129(9):969-74.
In 25 patients receiving allogeneic bone marrow transplants methotrexate was used to prevent acute graft-versus-host disease (GVHD). Acute GVHD, grades 2 to 4, developed in only 5 (20%) of the patients. The incidence of acute GVHD in other series of recipients of bone marrow transplants has ranged from 5% to 76%. A review of the literature suggests that this variation cannot be completely accounted for by age, type of disease treated by transplantation or type of GVHD prophylaxis. However, transfusion of allogeneic lymphocytes that have not been completely inactivated by irradiation (e.g., in platelet and granulocyte preparations) and inadequate isolation-decontamination procedures may increase the probability of GVHD following bone marrow transplantation.
在25例接受异基因骨髓移植的患者中，使用甲氨蝶呤预防急性移植物抗宿主病（GVHD）。仅5例（20%）患者发生了2至4级的急性GVHD。在其他系列骨髓移植受者中，急性GVHD的发生率在5%至76%之间。文献综述表明，这种差异不能完全用年龄、移植治疗的疾病类型或GVHD预防类型来解释。然而，输注未经辐射完全灭活的异基因淋巴细胞（如血小板和粒细胞制剂中的淋巴细胞）以及隔离去污程序不完善，可能会增加骨髓移植后发生GVHD的可能性。
